fbpx

molecules of the month

NVP-CLR457

oral pan-class IA PI3K inhibitor

Ph. I in advanced solid tumors

opt. from previous clinical candidate

J. Med. Chem

Novartis (NIBR), Basel, CH

NVP-CLR457 Chemical Structure, oral pan-class IA PI3K inhibitor - Novartis (NIBR), Basel, CH
6 mins read

Context. NVP-CLR457 (Novartis Institutes for BioMedical Research) is an oral, non-CNS-penetrating pan-class IA phosphoinositide 3-kinase (PI3K) inhibitor. Due to the key involvement of PI3K in the famed PI3K-Akt−mTOR pathway, whose deregulation has been observed in several cancers, it is no surprise that the last decade has seen over 600 medicinal chemistry-based publications and patents focusing on inhibitors targeting at least one of the 4 class I PI3K isoforms (α, β, δ, and γ). Consequently, over 30 anti-PI3K clinical candidates have been developed during this time, culminating in the approval of 5 isoform-selective agents: idelalisib (PI3Kδ), copanlisib (PI3Kα/δ), duvelisib (PI3Kδ/γ), alpelisib (PI3Kα), and the recently withdrawn umbralisib (PI3Kδ, CK1ε). This is a great teaching example for medicinal chemistry as the authors…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: